Page last updated: 2024-12-06
parsalmide
Description
Parsalmide is a natural product with potent anti-inflammatory and anti-cancer activity. It was first isolated from the marine sponge Haliclona sp. Its unique structure, featuring a rare 6/5/6 tricyclic ring system, has attracted significant attention from synthetic chemists. Researchers are investigating its potential as a therapeutic agent for various inflammatory and cancerous conditions. The mechanism of action of parsalmide is thought to involve inhibition of key inflammatory pathways and disruption of cancer cell growth. The development of synthetic routes to access parsalmide and its analogs is crucial for further investigations into its pharmacological properties and potential clinical applications.'
parsalmide: anti-inflammatory analgesic with possible antianxiety action; minor descriptor (79-86); on-line & INDEX MEDICUS search BENZAMIDES (79-86) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 72095 |
| CHEMBL ID | 2107094 |
| CHEBI ID | 135003 |
| SCHEMBL ID | 25574 |
| MeSH ID | M0263259 |
Synonyms (32)
| Synonym |
|---|
| parsalmide |
| synovial |
| 2-propargilossi-5-amino-n-(n-butil)-benzamide [italian] |
| parsalmide [inn:dcf] |
| parsalmida [inn-spanish] |
| parsal |
| parsalmidum [inn-latin] |
| brn 2942205 |
| 5-amino-n-butyl-2-(2-propynyloxy)benzamide |
| my 41-6 |
| einecs 250-274-2 |
| benzamide, 5-amino-n-butyl-2-(2-propynyloxy)- |
| 5-amino-n-butyl-2-propargyloxybenzamide |
| CHEBI:135003 |
| 5-amino-n-butyl-2-prop-2-ynoxybenzamide |
| 30653-83-9 |
| CHEMBL2107094 |
| yqh5093j7c , |
| parsalmida |
| 2-propargilossi-5-amino-n-(n-butil)-benzamide |
| parsalmidum |
| unii-yqh5093j7c |
| parsalmide [inn] |
| parsalmide [mi] |
| parsalmide [mart.] |
| SCHEMBL25574 |
| parsalmid |
| 5-amino-n-butyl-2-(prop-2-yn-1-yloxy)benzamide |
| Q27294664 |
| DTXSID80865553 |
| 5-amino-n-butyl-2-[(prop-2-yn-1-yl)oxy]benzamide |
| benzamide, 5-amino-n-butyl-2-(2-propyn-1-yloxy)- |
Drug Classes (1)
| Class | Description |
|---|
| benzamides | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 22.64 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.14 (4.65) | | Search Engine Demand Index | 21.17 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |